Abstract:Human genome sequencing studies have identified numerous loci associated with complex diseases, including Alzheimer’s disease (AD). However, translating human genetic and genomic findings (i.e., genome‐wide association studies [GWAS]) to pathobiology and therapeutic discovery remains a major challenge. Today, artificial intelligence and deep learning approaches that identify new risk genes and drug targets from human genome sequencing findings are enabling a more complete mechanistic understanding of disease biology. This is facilitating more rapid development of targeted therapeutic interventions for AD. We presented a network topology‐based deep learning framework to identify disease‐associated genes (NETTAG). NETTAG integrates multi‐genomics data and the human protein‐protein interactome to infer putative risk genes and drug targets impacted by GWAS loci. Specifically, we leveraged non‐coding GWAS loci effects on expression quantitative trait loci (eQTLs), histone‐QTLs, transcription factor binding‐QTLs, enhancers and CpG islands, promoter regions, open chromatin, and promoter flanking regions. The fundamental premise of NETTAG is that disease risk genes exhibit distinct functional characteristics compared to non‐risk genes, and can therefore be distinguished by their aggregated genomic features under the human protein interactome. Applying NETTAG to the latest AD GWAS data, we identified 156 putative AD‐risk genes (i.e., APOE, BIN1, GSK3B, MARK4, and PICALM). We showed that predicted risk genes are: 1) significantly enriched in AD‐related pathobiological pathways, 2) more likely to be differentially expressed in transcriptomes and proteomes of AD brains, and 3) enriched in druggable targets with approved medicines. Specifically, we showed that NETTAG‐predicted genes (e.g., MEF2D, CPLX2, KLF4, ACTL6B, P2RX7 and etc.) are differentially expressed in AD‐associated microglia and astrocytes from single‐nuclei RNA‐sequencing data of human postmortem brains with varying degrees of AD neurobiology. Via network‐based prediction, we identified multiple repurposable drug candidates (i.e., choline, deferoxamine and ibudilast) for potential treatment of AD. Our findings suggest that understanding human pathobiology and therapeutic development could benefit from network‐based deep learning methodology that utilizes GWAS findings with multimodal genomic analyses.

Multi-perspective Neural Network for Dual Drug Repurposing in Alzheimer’s Disease

AI-DrugNet: A network-based deep learning model for drug repurposing and combination therapy in neurological disorders

Advancement of Multi-Target Drug Discoveries and Promising Applications in the Field of Alzheimer's Disease.

Hybrid neural network approaches to predict drug-target binding affinity for drug repurposing: screening for potential leads for Alzheimer's disease

DeepDrug: An Expert-led Domain-specific AI-Driven Drug-Repurposing Mechanism for Selecting the Lead Combination of Drugs for Alzheimer's Disease

Drug repositioning for Alzheimer's disease with transfer learning

DOTA: Deep Learning Optimal Transport Approach to Advance Drug Repositioning for Alzheimer’s Disease

Development of multiple-target anti-Alzheimer′s agents

Network Proximity-based computational pipeline identifies drug candidates for different pathological stages of Alzheimer's disease

Modeling Path Importance for Effective Alzheimer's Disease Drug Repurposing

deepDR: a network-based deep learning approach to in silico drug repositioning

Application of Deep Learning for Studying NMDA Receptors

Discovery of Multitarget-Directed Ligands Against Alzheimer'S Disease Through Systematic Prediction of Chemical Protein Interactions

Identification of Multi-Target Anti-AD Chemical Constituents From Traditional Chinese Medicine Formulae by Integrating Virtual Screening and In Vitro Validation

Screening Novel Drug Candidates for Alzheimer's Disease by an Integrated Network and Transcriptome Analysis.

Novel Drug Discovery: Advancing Alzheimer's Therapy through Machine Learning and Network Pharmacology

Multidta: drug-target binding affinity prediction via representation learning and graph convolutional neural networks

Drug Repurposing for Effective Alzheimer's Disease Medicines: Existing Methods and Novel Pharmacoepidemiological Approaches

A Novel Deep Learning Model for Drug-drug Interactions

Drug Repositioning Via Multi-view Representation Learning with Heterogeneous Graph Neural Network

A Network‐based Deep Learning Framework Translates GWAS and Multi‐Omics Findings to Pathobiology and Drug Repurposing for Alzheimer’s Disease